Sahebnasagh et al. (2017): Successful Treatment of Acute Radiation Proctitis with Aloe Vera: A Preliminary Randomized Controlled Clinical Trial
Reference ↗ | |
---|---|
Title | Successful Treatment of Acute Radiation Proctitis with Aloe Vera: A Preliminary Randomized Controlled Clinical Trial |
Topic | Aloe vera |
Author | Sahebnasagh, A, Ghasemi, A, Akbari, J, Alipour, A, Lashkardoost, H, Ala, S, Salehifar, E |
Year | 2017 |
Journal | The Journal of Alternative and Complementary Medicine |
DOI | https://doi.org/10.1089/acm.2017.0047 |
Study Note
?
Brief summary
Study Design
Prospective / Retrospective Prospective: forward-looking, examples include clinical trials, cohort studies, and long-term observational studies;</br>Retrospective: backward-looking, relying on existing data, examples include case-control studies and retrospective cohort studies | ? |
---|---|
Monocentric / Multicentric Monocentric: conducted in one center/ hospital; </br>Multicentric: conducted in multiple centers/ hospitals | ? |
Blinding No: Open, all parties are aware of group assignments;</br>Single: one party is unaware of group assignments (generally participants);</br>Double: two parties are unaware of group assignments (generally the participants and the researchers); </br>Triple: concealing group assignment from additional parties | ? |
Is randomized | Yes |
Cross-over Participants alternate between different treatment groups or conditions over a specified period, allowing each participant to serve as their own control | No |
Number of arms | 2 |
Study characteristics
Inclusion criteria | ? |
---|---|
Exclusion criteria | ? |
N randomized | -999 |
Analysis PP: Per Protocol analysis, i.e. only participants included who adhered to the study protocol.</br>ITT: Intention-to-treat analysis, i.e. all randomized participants included regardless of any drop-outs or changes in assignment.</br>mITT: modified Intention-to-treat analysis can refer to analyses in which participants with missing outcome data are excluded or it can refer to analyses in which only participants who received at least one treatment dose are included. In this case, participants dropped out of the study prematurely for reasons unrelated to the treatment. | ? |
Specifications on analyses | ? |
Countries of data collection | ? |
LoE Level of evidence | ? |
Outcome timeline Data collection times | ? |
Characteristics of participants
Setting Refers to cancer therapy setting.</br>- Curative therapy: aims to completely eradicate a disease and achieve a full recovery; </br>- Neo-adjuvant therapy: form of curative therapy, given before the primary treatment for cancer (usually surgery); </br>- Adjuvant therapy: form of curative therapy, given after the primary treatment for cancer (usually surgery); </br>- Palliative therapy: focuses on providing relief from symptoms and improving the quality of life for patients, without necessarily targeting the underlying disease; </br>- Active surveillance: involves close monitoring of disease progression without any intervention (typically used for prostate cancer);</br>- No therapy setting: Patients who completed therapy/are currently not in cancer treatment, cancer survivors. | ? |
---|---|
Types of cancer "Other Cancers" means that only a subpopulation was specified, but further unspecified cancer types were included | ? |
Cancer stages Early Stage: generally refers to cancer that is localized to the area where it started, mostly stages I and II;</br>Advanced Stage: cancer that has spread beyond its original site, mostly stages III and IV, with stage IV indicating distant metastasis | ? |
Specifications on cancer stages | ? |
Comorbidities | ? |
Current cancer therapies | ? |
Specifications on cancer therapies | ? |
Previous cancer therapies | ? |
Gender | ? |
Gender specifications | ? |
Age groups | |
Age groups specification | ? |
Arms
Arm type Active control: group receives active treatment; </br>Passive control: for example treatment as usual, waiting control, no treatment | Intervention |
---|---|
Number of participants (arm) N randomized | 9 |
Drop-out Number of participants who left the study for any reason or did not provide information on every data collection date | 0 |
Drop-out reasons | NA |
Intervention | Aloe ointment |
Dosage and regime | 1g Aloe ointment (3% aloe powder, 2.3% white paraffin, 94.7% Vaseline) rectally 2x daily for 4 weeks.
+ all patients: 500mg Sulfasalazine 4x per day + all patients: radiotherapy |
One-time application | No |
Duration in days For long-term interventions, the number of days is an estimation.</br>A value of -999 indicates that the exact duration cannot be extracted from the study due to ambiguous or incomplete information. See Outcome timeline or Dosage and regime for further information. | 28 |
Side effects / Interactions | No adverse events were reported by the patients. |
Arm type Active control: group receives active treatment; </br>Passive control: for example treatment as usual, waiting control, no treatment | Placebo |
---|---|
Number of participants (arm) N randomized | 11 |
Drop-out Number of participants who left the study for any reason or did not provide information on every data collection date | 0 |
Drop-out reasons | NA |
Intervention | Placebo ointment |
Dosage and regime | 1g Placebo ointment (without aloe vera) rectally 2x daily for 4 weeks
+ all patients: 500mg Sulfasalazine 4x per day + all patients: radiotherapy |
One-time application | No |
Duration in days For long-term interventions, the number of days is an estimation.</br>A value of -999 indicates that the exact duration cannot be extracted from the study due to ambiguous or incomplete information. See Outcome timeline or Dosage and regime for further information. | 28 |
Side effects / Interactions | No adverse events were reported by the patients |
Outcomes
Toxicity
Outcome type As specificed by the authors | ? |
---|---|
Outcome specification | Clinical presentation score
Symptoms: Bleeding; Diahrroe; Fecal urgency; Abdominal/rectal pain Possibile score range: 0-16
0 = Not present 1 = Minor symptoms not requiring medications 2 = Moderate disturbing symptoms alleviated by analgesic or anticholineric medication 3 = Significant symptoms with bowel movement 4 = Significant discomfort on rest or symptoms requiring hospitalization |
Type of measurement | Scale |
Results during intervention - Results during intervention means that the time of data collection is during or shortly after the period of the intervention (e.g. on the last day or a few days after). The results therefore still relate to the direct effects of the intervention.</br>- Results after intervention means there is a longer break between the time of data collection and the end of the intervention, e.g. more than a week. The results relate more to long-term effects.</br>- If a categorization in Results during vs. after intervention is not possible (e.g. survival data), the results are summarized under Results after intervention under the headline "Overall". | Clinical presentation score per arm: Mean (SD)
The aloe arm had a decrease of symptoms from baseline = 4.3 (2.2) to week 4 = 1.2 (0.8). The placebo arm had a decrease of symptoms from baseline = 4.2 (1.2) to week 4 = 3.5 (1.1). The difference in the clinical presentation scroe between the arms was statistically significant (p=0.008). Significantly less diarrhoea (p=0.008) and fecal urgency (p=0.027) in the aloe arm compared to placebo arm. |
Results after intervention - Results during intervention means that the time of data collection is during or shortly after the period of the intervention (e.g. on the last day or a few days after). The results therefore still relate to the direct effects of the intervention.</br>- Results after intervention means there is a longer break between the time of data collection and the end of the intervention, e.g. more than a week. The results relate more to long-term effects.</br>- If a categorization in Results during vs. after intervention is not possible (e.g. survival data), the results are summarized under Results after intervention under the headline "Overall". | NA |
Risk of Bias Assessment: Cochrane RoB tool 2.0 | |
---|---|
Bias arising from the randomization process | ? |
Bias due to deviation from intended intervention (assignment to intervention) | ? |
Bias due to deviation from intended intervention (adhering to intervention) | NA |
Bias due to missing outcome data | ? |
Bias in measurement of the outcome | ? |
Bias in selection of the reported result | ? |
Other sources of bias | ? |
Overall RoB judgment | ? |
Quality of life
Outcome type As specificed by the authors | Primary |
---|---|
Outcome specification | The effect of radiation-induced symptoms on lifestyle
Grade 0 = Symptoms cause no effect on daily activity 1 = Symptoms cause inconveniences at least once a week 2 = Symptoms interfere with day-to-day activities more than once a week 3 = Symptoms interfere with routine activities on a daily basis 4 = Afraid to leave home with significant restriction in social life |
Type of measurement | Unspecified questionnaire |
Results during intervention - Results during intervention means that the time of data collection is during or shortly after the period of the intervention (e.g. on the last day or a few days after). The results therefore still relate to the direct effects of the intervention.</br>- Results after intervention means there is a longer break between the time of data collection and the end of the intervention, e.g. more than a week. The results relate more to long-term effects.</br>- If a categorization in Results during vs. after intervention is not possible (e.g. survival data), the results are summarized under Results after intervention under the headline "Overall". | ? |
Results after intervention - Results during intervention means that the time of data collection is during or shortly after the period of the intervention (e.g. on the last day or a few days after). The results therefore still relate to the direct effects of the intervention.</br>- Results after intervention means there is a longer break between the time of data collection and the end of the intervention, e.g. more than a week. The results relate more to long-term effects.</br>- If a categorization in Results during vs. after intervention is not possible (e.g. survival data), the results are summarized under Results after intervention under the headline "Overall". | NA |
Risk of Bias Assessment: Cochrane RoB tool 2.0 | |
---|---|
Bias arising from the randomization process | ? |
Bias due to deviation from intended intervention (assignment to intervention) | ? |
Bias due to deviation from intended intervention (adhering to intervention) | NA |
Bias due to missing outcome data | ? |
Bias in measurement of the outcome | ? |
Bias in selection of the reported result | ? |
Other sources of bias | ? |
Overall RoB judgment | ? |
Mental status/ function
Outcome type As specificed by the authors | Primary |
---|---|
Outcome specification | Psychosocial status: The patients were requested to weekly fill out the HAD form considering their feelings during past week. |
Type of measurement | HADS (Hospital Anxiety and Depression Scale) |
Results during intervention - Results during intervention means that the time of data collection is during or shortly after the period of the intervention (e.g. on the last day or a few days after). The results therefore still relate to the direct effects of the intervention.</br>- Results after intervention means there is a longer break between the time of data collection and the end of the intervention, e.g. more than a week. The results relate more to long-term effects.</br>- If a categorization in Results during vs. after intervention is not possible (e.g. survival data), the results are summarized under Results after intervention under the headline "Overall". | No difference between the arms. |
Results after intervention - Results during intervention means that the time of data collection is during or shortly after the period of the intervention (e.g. on the last day or a few days after). The results therefore still relate to the direct effects of the intervention.</br>- Results after intervention means there is a longer break between the time of data collection and the end of the intervention, e.g. more than a week. The results relate more to long-term effects.</br>- If a categorization in Results during vs. after intervention is not possible (e.g. survival data), the results are summarized under Results after intervention under the headline "Overall". | NA |
Risk of Bias Assessment: Cochrane RoB tool 2.0 | |
---|---|
Bias arising from the randomization process | ? |
Bias due to deviation from intended intervention (assignment to intervention) | ? |
Bias due to deviation from intended intervention (adhering to intervention) | NA |
Bias due to missing outcome data | ? |
Bias in measurement of the outcome | ? |
Bias in selection of the reported result | ? |
Other sources of bias | ? |
Overall RoB judgment | ? |
Toxicity
Outcome type As specificed by the authors | Primary |
---|---|
Outcome specification | Diarrhoea, proctitis, cystitis
Grades: 0 = No symptoms 1 = Minor symptomsrequiring no treatment 2 = Symptoms, that respond to simple outpatient management, and do not affect lifestyle 3 = Distressing symptoms affecting lifestyle; may necessitate hospital admissionor minor surgical intervention 4 = Major surgical intervention or long stay in the hospital necessary 5 = Fatal complications |
Type of measurement | RTOG Acute Radiation Morbidity Scoring Criteria (Radiation Therapy Oncology Group) |
Results during intervention - Results during intervention means that the time of data collection is during or shortly after the period of the intervention (e.g. on the last day or a few days after). The results therefore still relate to the direct effects of the intervention.</br>- Results after intervention means there is a longer break between the time of data collection and the end of the intervention, e.g. more than a week. The results relate more to long-term effects.</br>- If a categorization in Results during vs. after intervention is not possible (e.g. survival data), the results are summarized under Results after intervention under the headline "Overall". | Significantly lower RTOG toxicity score (p=0.0016) in the aloe arm compared to placebo arm.
Aloe arm: Baseline = 2.89 (2.1) to week 4 = 0.89 (1.0) Placebo arm: Baseline 3.64 (1.4) to week 4 = 3.09 (1.3) |
Results after intervention - Results during intervention means that the time of data collection is during or shortly after the period of the intervention (e.g. on the last day or a few days after). The results therefore still relate to the direct effects of the intervention.</br>- Results after intervention means there is a longer break between the time of data collection and the end of the intervention, e.g. more than a week. The results relate more to long-term effects.</br>- If a categorization in Results during vs. after intervention is not possible (e.g. survival data), the results are summarized under Results after intervention under the headline "Overall". | NA |
Risk of Bias Assessment: Cochrane RoB tool 2.0 | |
---|---|
Bias arising from the randomization process | ? |
Bias due to deviation from intended intervention (assignment to intervention) | ? |
Bias due to deviation from intended intervention (adhering to intervention) | NA |
Bias due to missing outcome data | ? |
Bias in measurement of the outcome | ? |
Bias in selection of the reported result | ? |
Other sources of bias | ? |
Overall RoB judgment | ? |
Funding and Conflicts of Interest
Funding | ? |
---|---|
Conflicts of Interest | ? |
Further points for assessing the study
Sample
Power analysis performed | ? |
---|---|
- Sample size corresponds to power analysis | ? |
- Reasons for insufficient sample size based on power analysis | ? |
If no power analysis performed: at least moderate sample size (n >= 30 per arm) | ? |
Ethnicity mentioned | ? |
Alternative Explanation
Other explanations for an effect besides the investigated intervention | ? |
---|---|
- Possibility of attention effects | ? |
- Possibility of placebo effects | ? |
- Other reasons | ? |
Statistics
Correct use of parametric and non-parametric tests Testing for normal distribution only necessary if parametric tests are used, NI: use of parametric tests without report of normal distribution testing | ? |
---|---|
Correction for multiple testing | ? |
Measurement of compliance | ? |
Consistent reporting in numbers (figures, flowchart, abstract, results) | ? |
Comprehensive and coherent reporting | ? |
Cross-over | ? |
- Sufficient washout period | ? |
- Tested for carry-over effects | ? |
- Tested for sequence effects | ? |
Interpretation of results
Effect sizes reported (clinical vs. statistical significance) | ? |
---|---|
Side effects systematically recorded | ? |
Side effects considered in result interpretation | ? |
Ethics votum | ? |
Additional Notes
?